RE:RE:RE:RE:RE:RE:RE:RE:RE:Ground Hog Day... Hi SF - like I say will not speculate on the motivations of others but instead try and look to results - both medical and corporate - for indications of where this is going.
Medically today`s ann might be regarded as moderately disappointing but only in the context of exceptionally high prior expectations. There is - as Enrique points out - the potential for the %s to improve yet and for this to obtain BTD and possibly become Standard of Care.
Does the current market cap reflect the potential of the Treasures bequeathed to the Company by Sherri McFarland? Not if those therapies are presently on an unimpeded path to Clinical fruition. Do we have any way to make even an educated guess as to whether that might be the case? Not in the absence of any updates from the Company.
Doesn`t this reticence hurt the Company`s ability to raise funds and avoid dilution by issuing shares at a price appropriate to the Company`s prospects? - or might the sp in fact reflect an accurate discount of the likelihood of the most game-changing aspects of this tech ever seeing the light of day?